Skip to content

OÜ PharmaFive

Registry code (registrikood) 14915186Private limited company (Osaühing)VAT EE102233694Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€5.3M
▼ 5.0% vs 2024
Profit before tax (2025)
-€6.0k
Employees, FTE (2025)
5
State taxes paid, last 4 quarters
€63k

Revenue, profit and employees, 2020–2025

€2.2M2020€3.6M2021€3.7M2022€3.9M2023€5.6M2024€5.3M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2020€2,235,973-€367,118-€367,117-€364,6172
2021€3,554,585-€108,375-€108,374-€472,9911
2022€3,744,144-€355,794-€355,792-€828,7832
2023€3,937,194-€5,199-€5,199-€968,0602
2024€5,564,934-€123,789-€123,785-€1,091,8464
2025€5,285,923-€6,007-€6,003-€1,097,8495

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2020€68,133€2,478,790€2,843,407—-€364,617
2021€63,797€2,202,119€2,675,110—-€472,991
2022€182,814€1,985,920€2,814,703—-€828,783
2023€242,975€955,391€1,923,451—-€968,060
2024€99,440€807,084€1,898,930—-€1,091,846
2025€142,899€626,803€1,724,652—-€1,097,849

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€0€3,864€980,9733
2022 Q2€0€7,158€998,4073
2022 Q3€10,799€13,167€872,4485
2022 Q4€0€10,077€900,9896
2023 Q1€1,139€12,999€871,0155
2023 Q2€0€7,300€805,5047
2023 Q3€48,103€13,905€954,9119
2023 Q4€0€15,437€1,136,33211
2024 Q1€1,289€19,241€1,408,03513
2024 Q2€0€22,081€1,364,54915
2024 Q3€0€19,173€1,323,04919
2024 Q4€1,596€22,150€1,451,01825
2025 Q1€3,831€23,490€1,456,07123
2025 Q2€19,205€26,539€1,442,00420
2025 Q3€22,476€28,218€1,186,25520
2025 Q4€22,978€26,691€1,264,54421
2026 Q1€12,859€27,338€1,285,05921
2026 Q2€10,858€22,980€1,256,77422
2026 Q3€16,244€28,329€1,257,40823

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ PharmaFive reported revenue of €5,285,923.

The company recorded a net loss of €6,003 in the 2025 financial year.

Revenue decreased by 5.0% from €5,564,934 in 2024 to €5,285,923 in 2025.

Revenue grew at a compound annual rate of 18.8% between 2020 and 2025.

Equity accounted for -175.2% of total assets of €626,803 at the end of the 2025 reporting period.

With 5 full-time-equivalent employees in 2025, revenue per employee was €1,057,185.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ PharmaFive reported €5,063,785 in turnover.

EMTA recorded 23 employees for the quarter ending Q3 2026, compared with 5 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.